The ATTEMPTS delivery systems for macromolecular drugs

Bibliography

• Bosslet K, Straub R, Blumrich M, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201
   PubMed Web of Science ®Google Scholar
• Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radial Biol 1991;60:85-100
   PubMed Web of Science ®Google Scholar
• Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1998;48:7022-32
   Google Scholar
• Syrigos KN, Epenetos AA. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res 1999;19:606-14
   Google Scholar
• Bagshawe KD. Antibody directed enzyme revive anti-cancer prodrugs concept. Br J Cancer 1987;56:531-2
   PubMed Web of Science ®Google Scholar
• Nguyen HT. Transport proteins. Clin Chem Lab Anim 1999;2:309-35
   Google Scholar
• Russell-Jones GJ, Alpers DH. Vitamin B12 transporters. Pharm Biotechnol 1999;12:493-520
   PubMedGoogle Scholar
• Greenwald RB, Conover CD, Choe YH. Poly (Ethylene Glycol) conjugated drugs and prodrugs: a comprehensive review. Crit Rev Ther Drug Carrier Syst 2000;17:101-61
   PubMed Web of Science ®Google Scholar
• Foldvari M, Mezei M. Intracellular delivery of drugs by liposomes containing P0 glycoprotein from peripheral nerve myelin into human M21 melanoma cells. J Pharm Sci 1991;80:1020-8
   PubMed Web of Science ®Google Scholar
• McNeil PL, Murphy RF, Lanni F, Taylor DL. A method for incorporating macromolecules into adherent cells. J Cell Biol 1984;98:1556-64
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Wylie DE, Schuster SM. Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem 1989;26:15494-500
   Google Scholar
• Foldvari M, Mezei C, Mezei M. Intracellular delivery of drugs by liposomes containing P glycoprotein from peripheral nerve myelin into human M21 melanoma cells. J Pharm Sci 1991;80:1020-8
   PubMed Web of Science ®Google Scholar
• Prior TI, Fitzgerald DJ, Pastan I. Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol. Biochem 1992;31:3555-9
   PubMed Web of Science ®Google Scholar
• Stenmark H, Moskaug JO, Madishus IH, et al. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. J Cell Biol 1991;113:1025-32
   PubMed Web of Science ®Google Scholar
• Ishihara H, Hara T, Aramaki Y, et al. Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-gamma and their uptake by isolated rat hepatocytes. Pharm Res 1990;7:542-6
   PubMed Web of Science ®Google Scholar
• Basu SK. Receptor-mediated endocytosis of macromolecular conjugates in selective drug delivery. Biochem Pharmacol 1990;40:1941-6
   PubMed Web of Science ®Google Scholar
• Wu GY, Wu CH. Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochem 1988;27:887-92
   PubMed Web of Science ®Google Scholar
• Leamon CP, Low PS. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem 1992;267(35):24966-71
   PubMed Web of Science ®Google Scholar
• Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996;12:575-625
   PubMed Web of Science ®Google Scholar
• Wu AM, Yazaki PY. Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 2000;44:268-83
   PubMedGoogle Scholar
• Niesner U, Halin C, Lozzi L, et al. Quantitation of the tumor targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjugate Chem 2002;13:729-36
   PubMed Web of Science ®Google Scholar
• Adams CP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of scFv antibodies. Cancer Res 1998;58:485-90
   PubMed Web of Science ®Google Scholar
• Juweid M, Neumann R, Paik R, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-53
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Wylie DE, Schuster SM. Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem 1989;26:15494-500
   Google Scholar
• Collen D, Stump DC, Gold HK. Thrombolytic therapy. Ann Rev Med 1988;39:405-23
   PubMed Web of Science ®Google Scholar
• Liang JF, Park YJ, Song H, et al. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. J Control Rel 2001;72:145-50
   PubMed Web of Science ®Google Scholar
• Liang JF, Li YT, Song H, et al. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. J Control Rel 2002;78:67-79
   PubMed Web of Science ®Google Scholar
• Naik SS, Liang JF, Park YJ, et al. Application of ‘ATTEMPTS’ for drug delivery. J Control Rel 2005;101:35-45
   PubMed Web of Science ®Google Scholar
• Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized Human Immunodeficiency Virus TAT transactivator protein. Cell 1988;55:1179-88
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 1988;55:1189-93
   PubMed Web of Science ®Google Scholar
• Fawell S, Seery J, Daikh Y, et al. TAT-mediated delivery of heterogeneous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-8
   PubMed Web of Science ®Google Scholar
• Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991;88:1864-8
   PubMed Web of Science ®Google Scholar
• Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997;88:223-33
   PubMed Web of Science ®Google Scholar
• Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 TAT protein. EMBO J 1991;10:1733-9
   PubMed Web of Science ®Google Scholar
• Derossi D, Joliot AH, Chassaings G, Prochiantz A. The third helix of the Anetennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269:10444-50
   PubMed Web of Science ®Google Scholar
• Mitchell DJ, Kim DT, Steinman L, et al. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000;56:318-25
   PubMedGoogle Scholar
• Suzuki T, Futaki S, Niwa M, et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002;277:2437-43
   PubMed Web of Science ®Google Scholar
• Futaki S, Nakase I, Suzuki T, et al. Translocation of branched-chain arginine peptides through cell membrane: flexibility in the spatial disposition of positive charges in membrane-permeable peptides. Biochem 2002;41:7925-30
   PubMed Web of Science ®Google Scholar
• Chang LC, Lee HF, Yang ZQ, Yang VC. Low molecular weight protamine (LMWP) as non-toxic heparin/LMWH antidote: [I]: preparation and characterization. AAPS PharmSci 2001;3(2):Article 17
   Google Scholar
• Chang LC, Liang JF, Lee LM, Yang VC. Low molecular weight protamine (LMWP) as non-toxic heparin/LMWH antidote: [II]: in vitro evaluation of efficacy and toxicity. AAPS PharmSci 2001;3(2):Article 18
   Google Scholar
• Lee LM, Chang LC, Wrobleski S, et al. Low molecular weight protamine (LMWP) as non-toxic heparin/LMWH antidote: [III]: preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci 2001;3(2):Article 19
   Google Scholar
• Niesner U, Halin C, Lozzi L, et al. Quantitation of the tumor targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002;13:729-36
   PubMed Web of Science ®Google Scholar
• Yang VC, Liang JF, Park YJ. PTD-mediated drug delivery system. US20030219378; 2003
   Google Scholar
• Kwon YM, Li YT, Liang JF, et al. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release 2008; published online 26 June 2008, doi:10.1016/j.jconrel.2008.06.017
   Google Scholar
• Park YJ, Chang LC, Liang JF, et al. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J 2005;19(11):1555-7
   PubMed Web of Science ®Google Scholar
• Li YT, Kwon YM, Spangrude GJ, et al. Preliminary in vivo evaluation of the PTD-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A. Published online 23 Sep 2008, doi:10.1002/jbm.a.32204
   Google Scholar
• Mashburn LT, Wriston JC Jr. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:450-2
   PubMed Web of Science ®Google Scholar
• Borella L, Hamlin NM, Hiramoto R. Hematological changes in tumor-bearing mice treated with L-asparaginase active guinea pig serum. Proc Soc Exp Biol Med 1969;132:1186-90
   PubMed Web of Science ®Google Scholar
• Chari RVJ. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998;31:89-104
   PubMed Web of Science ®Google Scholar
• Laguzza BC, Nicholis CL, Briggs SL, et al. Corvalan, new antitumor monoclonal antibody-vinca conjugate LY203725 and related compounds: design, preparation and representative in vivo activity. J Med Chem 1989;32:548-55
   PubMed Web of Science ®Google Scholar
• Trouet A, Masquelier M, Baurain R, Campeneere DD. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 1982;79:626-9
   PubMed Web of Science ®Google Scholar
• Schneck D, Butler F, Dugan W, et al. Disposition of a murine monoclonal antibody-Vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinoma. Clin Pharmacol Ther 1990;47:36-41
   PubMed Web of Science ®Google Scholar
• Schneck D, Butler F, Dugan W, et al. Phase I studies with a murine monoclonal antibody-Vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinoma. Antibody Immunoconjugates and Radiopharm 1989;2:93-100
   Google Scholar
• Singh M, Ghose T, Kralovec J, et al. Inhibition of human renal cancer by monoclonal antibody-linked methotrexate in an ascites tumor model. Cancer Immunol Immunother 1991;32:331-4
   PubMed Web of Science ®Google Scholar
• Liu C, Tadayoni BM, Bourret KM, et al. Elucidation of a large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996;93:8618-23
   PubMed Web of Science ®Google Scholar
• Kratz F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. Chem Med Chem 2008;3:20-53
   Google Scholar
• Houston TA. Painting the target around the arrow: two-step prodrug therapies from a carbohydrate chemist's perspective. Curr Drug Deliv 2007;4:264-8
   PubMedGoogle Scholar
• Bader H, Ringsdorf H, Schmidt B. Water-soluble polymers in medicine. Angew Makromol Chem 1984;123:457-85
   Google Scholar
• Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv Polym Sci 1995;122:55-123
   Web of Science ®Google Scholar
• Duncan R. Drug polymer conjugates: potential for improved chemotherapy. Cancer Res 1992;46:175-210
   Google Scholar
• Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992;3:351-62
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000;65:271-84
   PubMed Web of Science ®Google Scholar
• Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992;9:135-87
   PubMed Web of Science ®Google Scholar
• Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta 2001;515:167-76
   Google Scholar
• Kopecek J, Kopeckova P, Minko T, Lu ZR. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61-81
   PubMed Web of Science ®Google Scholar
• Rowley GF, Rubenstein KE, Huisjen J, Ullman EF. Mechanism by which antibodies inhibit heptan-malate dehydrogenase conjugates. J Biol Chem 1975;250:3759-66
   PubMed Web of Science ®Google Scholar